Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: resume (344), start again (306), save (202)

Cetuximab-Irinotecan (21day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-IRINOTECAN (21 day) This regimen may require funding Regimen • Col
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Irinotecan.pdf

Cetuximab (500)-Fluorouracil-Folinic Acid-Irinotecan

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB(500)-FLUOROURACIL-FOLINIC ACID (Modified de Gramont)IRINOTECAN Reg
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab500-Fluorouracil-FolinicAcid-Irinotecan.pdf

Elranatamab

Description: Chemotherapy Protocol ELRANATAMAB This protocol may require funding Regimen • Elranatamab Indication • Monotherapy for the treatment of adult patients with relapsed and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Elranatamab-Ver2.pdf

Tarlatamab (EAMS)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarlatamab is indicated as monotherapy for the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel-PertuzumabTrastuzumab (EC-PPH) Indication • Neo
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description: Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUMAB Regimen • Breast-Pembrolizumab with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

UHS AR 23-24 Final

Description: 2023/24 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2023/24 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-23-24-Final.pdf

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description: Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

AmB LEAM (split)-Lomustine-Cytarabine-Etoposide-Melphalan

Description: Chemotherapy Protocol LYMPHOMA LOMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (LEAM) Ambulatory Regimen This regimen is for AMBULATORY C
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LEAM-split-Lomustine-Cytarabine-Etoposide-Melphalan.pdf

Papers Trust Board - 29 November 2022

Description: Date Time Location Chair Agenda Trust Board – Open Session 29/11/2022 9:00 - 13:20 Conference Room, Heartbeat/Microsoft Teams
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Trust-Board-29-November-2022.pdf

191 to 200 of 219

Previous … 18 19 20 21 22 Next